ER and immune-related signatures define benefit to palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ breast cancer patients in the NA-PHER2 trial.
Giampaolo Bianchini(Vita-Salute San Raffaele University), Luca Gianni(Fondazione Michelangelo), Alberta Locatelli(Vita-Salute San Raffaele University), Stefania Zambelli(San Raffaele University of Rome), Balázs Győrffy(Semmelweis University), Barbara Galbardi(Vita-Salute San Raffaele University), Mauro Mansutti(Ospedale Santa Maria della Misericordia di Udine), Maurizio Callari(Cancer Research UK), Giancarlo Bisagni, Marco Colleoni(European Institute of Oncology), Pinuccia Valagussa(Fondazione Michelangelo), Matteo Dugo(Fondazione IRCCS Istituto Nazionale dei Tumori), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Chanel E. Smart(Vita-Salute San Raffaele University), Maria Olivia Biasi(European Institute of Oncology), Lucia Del Mastro(Ospedale Policlinico San Martino), Lucia Viganò(Vita-Salute San Raffaele University), Luca Licata(Vita-Salute San Raffaele University), Giuseppe Viale(University of Milan), Claudio Zamagni(Policlinico S.Orsola-Malpighi)
Cited by 1
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k